Patient-reported Outcomes Following Percutaneous Ablation of Desmoid Tumors

NCT07755176 | Enrolling By Invitation

• 1 other identifier: 24-011797
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This study will evaluate patient-reported outcomes before and after percutaneous ablation of desmoid tumors. Adult participants undergoing ablation for desmoid tumor will complete surveys pre and post procedure to assess symptom burden, impact on daily life, early post-procedural pain and recovery, concomitant treatments, and radiological response following ablation.

Conditions

Desmoid Tumor; Aggressive Fibromatoses

Outcome Measures

Primary Outcomes (3)

• Change in desmoid tumor symptom severity following ablation

  Desmoid tumor symptom severity following ablation will be measured using the GODDESS© Desmoid Tumor Symptom Scale, a disease-specific patient-reported outcome measure assessing desmoid tumor-related symptoms. Scores will be calculated according to the validated GODDESS© scoring algorithm. Higher scores indicate greater symptom burden.

  Baseline; 7 days; 1, 3, 6, 12, and 24 months post-ablation

• Change in desmoid tumor impact following ablation

  Desmoid tumor impact following ablation will be measured using the GODDESS© Desmoid Impact Scale, a disease-specific patient-reported outcome measure assessing desmoid tumor-related symptoms on patients' daily lives and functioning. Scores will be calculated according to the validated GODDESS© scoring algorithm. Higher scores are expected to indicate greater disease-related impact.

  Baseline; 7 days; 1, 3, 6, 12, and 24 months post-ablation

• Change in post-procedural pain score

  The pain score is calculated from a 2 question self-report survey asking recipients to rate pain on a scale of 1-10. Higher scores indicate worse pain.

  Baseline; 7 days; 1 month and 3 months post-ablation

Secondary Outcomes (1)

• Radiological response following ablation

  Through 24 months post-ablation

Study Arms (1)

Desmoid Tumor Ablation Cohort

Adult participants undergoing percutaneous ablation for desmoid tumor who complete patient-reported outcome surveys before and after treatment.

Procedure: Desmoid tumor ablation

Interventions

Desmoid tumor ablation PROCEDURE

Percutaneous ablation of desmoid tumor

Desmoid Tumor Ablation Cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients undergoing ablation of desmoid tumor at Mayo Clinic Rochester.

You may qualify if:

• Adult patients undergoing ablation for desmoid tumor.

You may not qualify if:

• Declines to participate in research.

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

MeSH Terms

Conditions

Desmoid Tumors

Condition Hierarchy (Ancestors)

Fibroma; Neoplasms, Fibrous Tissue; Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms

Study Officials

• Rebecca Hibbert, M.D.

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: August 5, 2026
• First Posted: August 10, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2028
• Last Updated: August 10, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)